ACI
APLS

AMP Capital Investors’s Apellis Pharmaceuticals APLS Stock Holding History

AMP Capital Investors’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-11,600
Closed -$333K – 1188
2020
Q1 		$333K Buy
+11,600
New +$412K ﹤0.01% 951

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

AMP Capital Investors's APLS Position: Q2 2020 in Review

AMP Capital Investors sold out of Apellis Pharmaceuticals (APLS) in Q2 2020, closing a stake of 11,600 shares — an estimated $333K sold.

AMP Capital Investors first reported a position in APLS in Q1 2020 and held it in 1 quarter. The position peaked at $333K in Q1 2020. 142 funds tracked by Wall St. Rank hold APLS as of Q2 2020.

  • AMP Capital Investors reported no remaining Apellis Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • AMP Capital Investors sold 11,600 Apellis Pharmaceuticals shares in Q2 2020, an estimated $333K.
  • AMP Capital Investors first reported a position in Apellis Pharmaceuticals in Q1 2020 and held it in 1 quarter.
  • AMP Capital Investors's Apellis Pharmaceuticals position peaked at $333K in Q1 2020.
  • 142 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2020.

Based on AMP Capital Investors's 13F filing for Q2 2020, filed 14 Aug 2020.